TiGenix obtains manufacturing license for European production facility
"I'd like to commend our manufacturing team responsible for building and validating our production plant in record time and passing the inspection of the Dutch regulatory authorities with flying colors," said Eduardo Bravo, CEO of TiGenix. "Our state-of-the-art manufacturing site is unique in Europe as it is 100% geared towards the production of innovative cell therapy products. It provides us with crucial manufacturing capabilities to support the anticipated growth in demand for ChondroCelect for cartilage repair, and has sufficient capacity for the production of our advanced stem cell therapy products."
Most read news
Organizations
Other news from the department manufacturing
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.